FDA Modifies CAR-T Risk Strategies to Lower Healthcare Burden

News
Article

A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.

Nicole Verdun, MD, the director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research

Nicole Verdun, MD

Credit: CBER, FDA

The FDA has modified its Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies to minimize burdens on healthcare systems.1

The REMS have been modified to remove the requirements for educational and training materials regarding the risks of cytokine release syndrome (CRS) and neurological toxicities associated with approved CAR T-cell therapies Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), and Yescarta (axicabtagene ciloleucel).

The FDA notice stated that information about the risks of these adverse effects (AEs) are “conveyed adequately” on current product labeling as well as boxed warnings. The FDA also removed the requirement to report AEs suggestive of CRS or neurological toxicities to the REMS. Notably, the FDA recently required approved CAR-T labels to include boxed warnings for T-cell malignancies after treatment.2

“Since [the product was approved], we have become aware of the risk of T-cell malignancies, with serious outcomes, including hospitalization and death, following treatment with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies,” Nicole Verdun, MD, the director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, wrote.2 “FDA identified postmarketing adverse event and clinical trial reports describing [the] occurrence of mature T-cell malignancies, including CAR-positive tumors, following treatment with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies... Furthermore, we consider the serious risk of T-cell malignancy to be applicable to all BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.”

READ MORE: Galapagos Pauses Enrollment in Multiple Myeloma CAR-T Trial After Parkinsonism Case

As CAR T-cell therapies become more ingrained in the treatment landscape, strategies continue to evolve to regulate these therapies. Also examining REMS, a recent study published in Blood Advances has found that a shorter, flexible monitoring period after CAR T-cell therapy beyond 14 days appears safe and feasible and may help to improve access to these therapies.4

The new research, conducted by first author Nausheen Ahmed, MD, Associate Professor, Hematologic Malignancies and Cellular Therapeutics, and Assistant Director, Cellular Therapeutics, and Medical Director, BMT Survivorship Program, University of Kansas Medical Center, and colleagues found that instances of new-onset CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) are rare after 14 days.4

“As a clinician that administers CAR-T, I’ve had many patients who have not been able to receive it because of barriers to access,” Ahmed said in a statement.5 “I have patients who are traveling for 6 or even 8 hours to get treatment."

The research aimed to decrease the burden placed on patients for CAR T-cell therapy, who currently must remain close to the treatment center for 4 weeks to monitor and manage toxicities. The guidelines also advise against driving for 8 weeks after infusion.

REFERENCES
1. Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare Delivery System. News release. FDA. June 26, 2024. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor-car-t-cell
2. FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. April 18, 2024. News release. FDA. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed
3. 2024 Safety and Availability Communications. FDA. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2024-safety-and-availability-communications
4. Ahmed N, Wesson W, Lutfi F, et al. Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel. Blood Adv. Published online July 23, 2024. doi: 10.1182/bloodadvances.2023012549
5. Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL. News release. ASCO Post. July 24, 2024. https://ascopost.com/news/july-2024/shortening-fda-mandated-car-t-cell-therapy-monitoring-periods-could-improve-access-to-treatment-in-patients-with-dlbcl/
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Related Content
© 2024 MJH Life Sciences

All rights reserved.